Highlights Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 23/05/2025 BST			5-day change	1st Jan Change
137.00 ^USD	-0.75%		-4.08%	-30.28%

05-23	Trump's Tariff Blitz Roils Markets, Targets EU and Apple
05-23	Redburn Atlantic Adjusts Price Target on IQVIA Holdings to $188 From $255, Maintains Buy Rating	MT

Highlights

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials	05-16	CI
IQVIA Teams Up With SCRI to Expedite Development of New Cancer Therapies	05-16	MT
Lupin Limited Receives Approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 10 Mg, 15 Mg	05-15	CI
London Calling: Markets Jump	05-08
Tranche Update on IQVIA Holdings Inc.'s Equity Buyback Plan announced on October 31, 2013.	05-06	CI
Sector Update: Health Care Stocks Fall Pre-Bell Tuesday	05-06	MT
IQVIA beats quarterly profit estimates on higher demand for research services	05-06	RE
IQVIA Holdings' Q1 Adjusted Earnings, Revenue Rise; Raises 2025 Revenue Guidance	05-06	MT
Earnings Flash (IQV) IQVIA Holdings Posts Q1 Revenue $3.83B, vs. FactSet Est of $3.77B	05-06	MT
Earnings Flash (IQV) IQVIA Holdings Reports Q1 Adjusted EPS $2.70, vs. FactSet Est of $2.63	05-06	MT
IQVIA Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-06	CI
IQVIA Holdings Inc. Revises Earnings Guidance for the Full Year 2025	05-06	CI
Alembic Pharmaceuticals Gets US FDA Final Nod for Carbamazepine Tablets	04-17	MT
Aurobindo Pharma Limited Receives Final ANDA Approval for Rivaroxaban Tablets USP, 2.5Mg and Tentative Approval for Other Strengthens of Rivaroxaban Tablets USP	04-12	CI
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Acetaminophen Injection, 10 Mg/mL (500Mg/50ML and 1000Mg/100ML) Bags	04-03	CI
IQVIA beats quarterly results estimates on analytics services demand	02-06	RE
IQVIA Holdings' Q4 Adjusted Earnings, Revenue Rise; 2025 Guidance Reaffirmed	02-06	MT
Earnings Flash (IQV) IQVIA Holdings Posts Q4 Revenue $3.96B, vs. FactSet Est of $3.93B	02-06	MT
Earnings Flash (IQV) IQVIA Holdings Posts Q4 Adjusted EPS $3.12, vs. FactSet Est of $3.11	02-06	MT
Tranche Update on IQVIA Holdings Inc.'s Equity Buyback Plan announced on October 31, 2013.	02-06	CI
IQVIA Holdings Inc. Reaffirms Earnings Guidance for the Full Year 2025	02-06	CI
IQVIA Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	02-06	CI
IQVIA Holdings Inc. announces an Increase in Equity Buyback.	02-04	CI
Barclays Adjusts IQVIA Holdings Price Target to $235 From $255, Maintains Overweight Rating	02-03	MT
BTIG Downgrades IQVIA Holdings to Neutral From Buy	02-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Highlights

Filters